CLINICAL TRIALS PROFILE FOR PRIMACOR

All Clinical Trials for PRIMACOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00543309 ↗	Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery	Terminated	American Heart Association	Phase 2	2007-10-01	The staged surgical pathway to treat children with single ventricle heart defects culminates with the Fontan operation. In this procedure, systemic venous return is rerouted directly to the pulmonary arteries, which serves to separate the systemic and pulmonary circulations. Although mortality following the Fontan operation is now uncommon, early postoperative morbidity including prolonged postoperative chest tube drainage and hospitalization remains significant. The efficacy of empiric inotropic, vasodilator and neurohumoral-inhibitory therapies in the perioperative period is unknown and practice varies widely between centers. The investigators will propose a single-center, randomized, double-blind, phase II clinical trial in children undergoing Fontan surgery. The investigators plan to compare the effects of perioperative nesiritide, milrinone and placebo infusions on the early postoperative clinical course and neurohumoral profile. The investigators hypothesize that, when compared to the milrinone and placebo groups, the nesiritide group will have more days alive and out of the hospital within the first 30 days after surgery.
NCT00543309 ↗	Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery	Terminated	John M Costello	Phase 2	2007-10-01	The staged surgical pathway to treat children with single ventricle heart defects culminates with the Fontan operation. In this procedure, systemic venous return is rerouted directly to the pulmonary arteries, which serves to separate the systemic and pulmonary circulations. Although mortality following the Fontan operation is now uncommon, early postoperative morbidity including prolonged postoperative chest tube drainage and hospitalization remains significant. The efficacy of empiric inotropic, vasodilator and neurohumoral-inhibitory therapies in the perioperative period is unknown and practice varies widely between centers. The investigators will propose a single-center, randomized, double-blind, phase II clinical trial in children undergoing Fontan surgery. The investigators plan to compare the effects of perioperative nesiritide, milrinone and placebo infusions on the early postoperative clinical course and neurohumoral profile. The investigators hypothesize that, when compared to the milrinone and placebo groups, the nesiritide group will have more days alive and out of the hospital within the first 30 days after surgery.
NCT01621971 ↗	Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients	Completed	Konkuk University Medical Center	Phase 3	2003-01-01	Our main hypothesis is that inhalation of milrinone can reduce the elevated pulmonary arterial pressure due to severe mitral valve regurgitation without compromising systemic hemodynamics. Therefore, the effects of a brief inhaled milrinone (IH) on pulmonary artery pressure are determined and compared to those of intravenous milrinone (IV) in severe mitral regurgitation patients undergoing mitral valve surgery.
NCT01725776 ↗	Inhaled Milrinone in Cardiac Surgery	Completed	Canadian Institutes of Health Research (CIHR)	Phase 2	2006-12-01	The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.

Clinical Trial Conditions for PRIMACOR

Condition Name

Condition Name for PRIMACOR
Intervention	Trials
Pulmonary Hypertension	3
Heart Failure, Diastolic	1
Septic Shock	1
Hypoxemic Respiratory Failure	1

Condition MeSH

Condition MeSH for PRIMACOR
Intervention	Trials
Hypertension, Pulmonary	6
Hypertension	5
Heart Failure	2
Persistent Fetal Circulation Syndrome	1

Clinical Trial Locations for PRIMACOR

Trials by Country

Trials by Country for PRIMACOR
Location	Trials
United States	15
Thailand	2
Korea, Republic of	1
Sweden	1
China	1

Trials by US State

Trials by US State for PRIMACOR
Location	Trials
Utah	1
Texas	1
Rhode Island	1
Pennsylvania	1
Ohio	1

Clinical Trial Progress for PRIMACOR

Clinical Trial Phase

Clinical Trial Phase for PRIMACOR
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for PRIMACOR
Clinical Trial Phase	Trials
Completed	5
Recruiting	4
Withdrawn	1

Clinical Trial Sponsors for PRIMACOR

Sponsor Name

Sponsor Name for PRIMACOR
Sponsor	Trials
St. Justine's Hospital	1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1
Montreal Heart Institute	1

Sponsor Type

Sponsor Type for PRIMACOR
Sponsor	Trials
Other	20
NIH	1

Last updated: April 28, 2026

Primacor (milrinone): What do the clinical, market, and projection signals show?

What is Primacor and where does it sit clinically?

Primacor is the brand name for milrinone, an intravenous phosphodiesterase (PDE) 3 inhibitor used in acute or decompensated heart failure settings, typically to improve hemodynamics. In clinical practice, milrinone is used for short-term inpatient management of severe heart failure and as an inotrope where rapid hemodynamic support is needed.

Clinical trial update No credible, ongoing late-stage (Phase 3) or recent pivotal trials for milrinone under the Primacor brand were identified in the public clinical-trial record stream used for branded-drug surveillance (e.g., ClinicalTrials.gov) during the current review horizon. Milrinone remains a legacy inotrope with primarily established use patterns rather than a drug with a current Phase 3 development pipeline that would drive near-term labeling expansion.

Implication for development risk

• Low probability of near-term label expansion driven by new efficacy readouts for Primacor in the typical “branded program” sense.
• Any future activity is more likely to be formulation, supply, or comparative effectiveness rather than de novo Phase 3 efficacy.

Regulatory anchoring Milrinone is an established medicine with an established safety and efficacy profile tied to historical trials and decades of use in acute heart failure practice; current competitive differentiation in this segment comes from inotrope choice, hospital protocols, and access/cost rather than new clinical efficacy claims.

---

What does the market look like for IV milrinone, and who competes?

Milrinone’s market position is shaped by three forces: (1) institutional inotrope formularies, (2) comparative use versus other IV inotropes, and (3) procurement and supply continuity.

Competitive landscape (inotrope substitutes) Across acute heart failure and peri-operative support use, milrinone competes with:

• Dobutamine (another inotrope with common guideline use and broad familiarity)
• Inodilators and vasopressors depending on hemodynamic profile (including agents used in cardiogenic shock or severe decompensation protocols)
• Other branded products where hospitals standardize pathways for ICU inotrope selection

Procurement dynamics Inotropes like milrinone typically trade in a market where:

• Hospitals run protocol-based selection and dosing targets
• Product choice often follows availability, acquisition cost, and pharmacy standardization
• Contracting can shift between suppliers even when clinical practice remains stable

Branded vs generic reality Primacor is widely understood as a branded legacy product whose market share is strongly influenced by generic availability of milrinone. That compresses pricing power and increases the importance of supply reliability and pack economics.

Market conclusion for investment-grade positioning

• Revenue growth for Primacor-style legacy inotropes is generally limited by generic price pressure and the narrow nature of use cases (acute inpatient settings).
• Growth, where it exists, is usually driven by volume stability (hospital demand) and supply continuity, not by new clinical adoption curves.

---

What are practical sales drivers and headwinds for Primacor?

Primary demand drivers

• Persistent hospital ICU and acute heart failure admissions where IV inotrope therapy is selected
• Inotrope protocols that retain milrinone for patients where clinicians favor its hemodynamic profile

Key headwinds

• Generic competition that compresses realized prices
• Institutional preference shifts to other inotropes based on local outcomes data, side-effect profiles, and protocol updates
• Hospital cost controls and contracting cycles that favor lowest-cost supply

---

What projections are reasonable for Primacor’s near- and mid-term performance?

Because the product sits in a legacy, protocol-driven inotrope category without a visible late-stage branded development pipeline, projections should be read as volume-and-price mechanics, not as pipeline-driven upside.

Projection framework (mechanics-based)

1) Volume

• Typically stable to modestly varying with acute heart failure hospitalization volumes.
• Uptake can change if a hospital updates protocols, but the overall category tends to be sticky once pathways are set.

2) Price

• Pricing usually trends toward or below historic brand levels under generic pressure.
• Realized price is most sensitive to tender outcomes and supplier switching.

3) Net revenue

• Net growth depends on whether volume expansion offsets price compression.
• Without new clinical expansion, upside is usually limited.

Near-term view (0-3 years)

• Modest revenue trajectory, with the dominant factor being price maintenance through supply and contracting rather than brand differentiation.
• Clinical activity is not expected to rebase the category the way a new Phase 3 program could.

Mid-term view (3-7 years)

• Continuation of generic-driven pricing pressure.
• Real growth requires either (a) a shift in hospital protocol intensity toward milrinone, or (b) supply/contract advantages that prevent further erosion in net price.

Net projection outcome For a legacy IV inotrope with generic competition and no visible current pivotal program, the most probable outcome is range-bound revenue with gradual price decay and limited structural growth.

---

What would change the trajectory (signals to watch)?

Even without new Phase 3 data, trajectory can move with category dynamics:

Category protocol changes

• If hospital pathways increasingly favor milrinone for certain phenotypes, volume can rise.
• If protocols shift to alternative inotropes in standardized shock or decompensation algorithms, milrinone volume can decline.

Supply and contracting

• Supplier continuity and favorable tender outcomes can slow price erosion.
• Supply constraints that limit availability can temporarily protect realized pricing, but they do not create durable growth without protocol support.

Formulation and delivery innovations

• Any meaningful shift in stability, administration, or ease-of-use can affect adoption, but it still competes against generic economics.

---

Key Takeaways

• Primacor (milrinone) is a legacy IV PDE-3 inotrope used for acute hemodynamic support in decompensated heart failure settings.
• No credible late-stage branded clinical trial signal appears to be driving a near-term efficacy or label expansion for Primacor.
• Market outcomes are dominated by hospital protocol stickiness and generic price compression, not by new clinical differentiation.
• Revenue projection is most consistent with range-bound performance where contracting and supply determine net price, and category demand determines volume.
• Structural upside likely requires protocol shifts favoring milrinone or supply advantages that protect realized pricing.

---

FAQs

1) Is Primacor a current growth pipeline product?

No. Primacor is a legacy IV inotrope with clinical use anchored in established practice rather than a visible active branded late-stage development trajectory.

2) What most determines Primacor revenue in practice?

Net price from tenders/contracting and volume from acute inpatient demand where hospital protocols select milrinone.

3) Who are the closest therapeutic substitutes?

Common substitutes are other IV inotropes used in similar acute heart failure or decompensation settings, including dobutamine and protocol-dependent inotrope combinations.

4) Are new trials likely to change the label soon?

The near-term label-rebasing opportunity is limited because there is no clear current signal of pivotal branded Phase 3 development for Primacor.

5) What is the best indicator to track for forward projections?

Track hospital formulary/protocol updates and net price trends driven by generic competition and contract outcomes.

---

References

1. U.S. Food and Drug Administration. Primacor (milrinone lactate) prescribing information. FDA label database.
2. ClinicalTrials.gov. Search results for milrinone and Primacor (milrinone lactate) clinical trials.